Literature DB >> 30201233

Peri-operative allogeneic blood transfusion is associated with poor overall survival in advanced epithelial ovarian Cancer; potential impact of patient blood management on Cancer outcomes.

Joseph P Connor1, Andrea O'Shea2, Kevin McCool3, Emmanuel Sampene4, Lisa M Barroilhet2.   

Abstract

BACKGROUND: Transfusion related immune modulation associated with red blood cell (RBC) transfusion is thought to result in decreased cancer survival. Results in epithelial ovarian cancer (EOC) have been mixed however most suggest worse oncologic outcomes in patients who were transfused at the time of debulking surgery. The impact of restrictive transfusion strategies on this patient population is currently not known.
METHODS: We conducted a retrospective study of women with EOC. The study population was divided into two groups based on whether they were transfused RBCs during the peri-operative period or not. Clinical characteristics and prognosticators were compared between groups. Overall survival was compared between groups based on transfusion status and other known prognostic factors. Cox proportional hazard modeling was used to examine the association between the prognostic factors and the study endpoint.
RESULTS: Sixty-six percent of women were transfused. Transfusion was associated with CA125, the use of neoadjuvant chemotherapy (NACT), surgical blood loss, and anemia. The mean pre-transfusion Hgb was 7.8 + 0.6 g/dL and 94% had a hemoglobin level greater than the transfusion threshold of 7 g/dL. RBC transfusion, suboptimal debulking, anemia, and NACT were associated with decreased survival. Only RBC transfusion and suboptimal debulking status remained significant in a multivariate model.
CONCLUSIONS: Peri-operative RBC transfusion compromises survival in ovarian cancer supporting the need to minimize the use of transfusion at the time of debulking surgery. Adherence to evidence-based transfusion guidelines offers an opportunity to reduce transfusion rates in this population with a resulting positive influence on survival.
Copyright © 2018 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Ovarian cancer; Patient blood management; Survival; Transfusion

Mesh:

Substances:

Year:  2018        PMID: 30201233     DOI: 10.1016/j.ygyno.2018.08.040

Source DB:  PubMed          Journal:  Gynecol Oncol        ISSN: 0090-8258            Impact factor:   5.482


  6 in total

1.  MicroRNA Profiling of Exosomes Derived from Red Blood Cell Units: Implications in Transfusion-Related Immunomodulation.

Authors:  Haobo Huang; Jinfeng Zhu; Liping Fan; Qiuyan Lin; Danhui Fu; Biyu Wei; Shijin Wei
Journal:  Biomed Res Int       Date:  2019-06-13       Impact factor: 3.411

2.  Blood cell-derived extracellular vesicles: diagnostic biomarkers and smart delivery systems.

Authors:  Limei Xu; Yujie Liang; Xiao Xu; Jiang Xia; Caining Wen; Peng Zhang; Li Duan
Journal:  Bioengineered       Date:  2021-12       Impact factor: 3.269

3.  Perioperative red blood cell transfusion is associated with poor functional outcome and overall survival in patients with newly diagnosed glioblastoma.

Authors:  Matthias Schneider; Niklas Schäfer; Anna-Laura Potthoff; Leonie Weinhold; Lars Eichhorn; Johannes Weller; Elisa Scharnböck; Christina Schaub; Muriel Heimann; Erdem Güresir; Felix Lehmann; Hartmut Vatter; Ulrich Herrlinger; Patrick Schuss
Journal:  Neurosurg Rev       Date:  2021-09-04       Impact factor: 3.042

4.  Correlation between hematological parameters and outcome in patients with locally advanced cervical cancer treated by concomitant chemoradiotherapy.

Authors:  Christine Gennigens; Marjolein De Cuypere; Laurence Seidel; Johanne Hermesse; Annelore Barbeaux; Frédéric Forget; Adelin Albert; Guy Jerusalem; Frédéric Kridelka
Journal:  Cancer Med       Date:  2020-09-20       Impact factor: 4.452

5.  Treatment of anemia in cancer patients undergoing chemotherapy with intravenous ferric carboxymaltose without erythropoiesis-stimulating agents.

Authors:  Hikmat Abdel-Razeq; Salwa S Saadeh; Razan Malhis; Sameer Yasser; Hazem Abdulelah; Rana Eljaber; Amer Kleib; Rouba Ismael
Journal:  Ther Adv Med Oncol       Date:  2020-09-09       Impact factor: 8.168

Review 6.  Critically ill patients with cancer: A clinical perspective.

Authors:  Frank Daniel Martos-Benítez; Caridad de Dios Soler-Morejón; Karla Ximena Lara-Ponce; Versis Orama-Requejo; Dailé Burgos-Aragüez; Hilev Larrondo-Muguercia; Rahim W Lespoir
Journal:  World J Clin Oncol       Date:  2020-10-24
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.